Tryptyr
(Acoltremon)ApprovedSmall molecule
This eye drop medication is used to treat dry eye disease by stimulating the eyes to produce more tears, helping to restore adequate moisture to the eyes.[2] Tryptyr is currently approved and in use across 2 indications[4].[1]
Tryptyr is one of 29 small molecule programs targeting Eye Disease. It is currently in Approved.
2
Indications
2
Total Trials
2
Active Trials
28
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
5
Patents
Pipeline
Status by Indication[4][1]
Competition
Competitive Landscape
29 competitors in Eye Disease
#DrugCompanyPhaseTrials
1Chantix
PPrism Pharmaceuticals
Approved
Rapamune
PPrism Pharmaceuticals
Approved
Empaveli
Apellis PharmaceuticalsApproved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Neo-Synephrine
EExela Pharma Sciences, LLC.
Approved
Heparin Sodium
BBaxter Healthcare Corporation
Approved
Tryptyr
FFalcon
Approved
AZR-MD-001
AAzura Ophthalmics
Phase 3
Miebo
BBausch & Lomb Incorporated
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[5]
May 28, 2025
TRYPTYR
NDA NDA217370
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Tryptyr drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Acoltremon. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]